Innovation Pharmaceuticals Inc (IPIX)

[MinnieM]

You are comparing oranges to apples. The post I responded to said he had interim results. I say he doesn't have the interim results for prurisol.

MDA didn't drop B-OM. The trial was pulled due to too much competition with another trial at that location.

DF had a lot of delays... non issue since out of company control.

UofB AML expected trial wasn't under Leo's control. The DF trial took too long and UofB didn't have funds when it was finally done. They actually asked Leo for help funding the trial, but, Leo couldn't since the company financing was negatively affected by the five or so hit pieces in 2015. University of Bologna, and Istituto Scientifico Romagnolo per lo Sudio e la Cura dei Tumori (IRST) scientists along with some from University of Ferrara-Arcispedale Saint'Anna presented data this year (2017) at European Hematology Association EHA on kevetrin and Acute Myeloid Leukemia AML. They wouldn't have done so if they'd lost confidence in the drug. Lack of funding was the issue.

http://learningcenter.ehaweb.org/eha/2017/22nd/180680/roberta.napolitano.kevetrin.preclinical.study.of.a.new.compound.in.acute.html
(Abstract release date: May 18, 2017)






In Reply to 'Amatuer17'
Hope your trust survives.

I remember MDA dropping from B-OM - there was no progress - he did not announce - it was skipped in a 10-q

DF delay in mid cohort - was not announced - it was mentioned as BTW

UOB-AML trial cancellation was nt announced for long and it was in one of the 10-q or 10-k and then was added to a PR

So there is enough evidence about such timing the info release - if you do not want to call manipulation. So I personally will not be surprised if P results are not that good and reconfirm suspicion of skipping interim.